LONDON, Dec. 19, 2013 (GLOBE NEWSWIRE) -- Epiq Systems, Inc. (Nasdaq:EPIQ), a leading provider of managed technology for the global legal profession, has published a new best practice guide entitled "Management Guide: Bribery Act for Pharmaceutical Organizations" for companies in the UK pharmaceutical industry.
The UK Bribery Act 2010 (the "Act") introduced a new set of bribery offences and, in particular, widened the circle of pharmaceutical firms that need to address bribery risks. It applies not only to the actions of UK-incorporated companies and UK-formed partnerships, but also to companies and partnerships which carry out business in the UK regardless of where they were incorporated or formed. In addition, the Act pertains to employees of UK companies and any "associated persons," i.e., individuals who perform work for or on behalf of the company, such as contracted workers or subsidiaries.
"The pharmaceutical industry is already heavily regulated but companies operating in the sector must now also ensure that they are sufficiently prepared to respond to additional regulatory requirements," said Greg Wildisen, Managing Director, International, Epiq Systems. "Organisations must be able to monitor a wide range of activities using a variety of information management systems in order to demonstrate compliance."
The Management Guide is free to download at http://www.epiqsystems.co.uk/en-GB/resources/
About Epiq Systems
Epiq Systems is a leading global provider of technology-enabled solutions for electronic discovery, bankruptcy and class action administration. We offer full-service capabilities to support litigation, investigations, financial transactions, regulatory compliance and other legal matters. Our innovative technology and services, combined with deep subject-matter expertise, provide reliable solutions for the professionals we serve. Visit us online at www.epiqsystems.com.
CONTACT: Lew Schroeber, Investor Relations
Source: Epiq Systems, Inc.